Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 2, 2011, Pages 287-293

  Da Fonseca, Clovis O ^a   Simão, Marcela ^b   Lins, Igor R ^a   Caetano, Regina O ^b   Futuro, Débora ^b   Quirico Santos, Thereza ^b  

^a HOSPITAL UNIVERSITÁRIO ANTÔNIO PEDRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Glioblastoma; Intranasal administration; Perillyl alcohol; Terpene; Tumor topography

Indexed keywords

CORTICOSTEROID; PERILLYL ALCOHOL;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN RADIOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT DISEASE; SEX DIFFERENCE; SURVIVAL RATE; TUMOR LOCALIZATION;

ADMINISTRATION, INTRANASAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MONOTERPENES; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION;

EID: 78751632881     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0873-0     Document Type: Article

References (21)

1. P Auvinen R Tammi J Parkkinen M Tammi U Agren R Johansson P Hirvikoski M Eskelinen VM Kosma 2000 Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival Am J Pathol 156 529 536 1:STN:280:DC%2BD3c7jt1yhsQ%3D%3D 10666382
2. F Bokstein S Shpigel DT Blumenthal 2008 Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors Cancer 112 2267 2273 1:CAS:528:DC%2BD1cXmt1CnsL8%3D 10.1002/cncr.23401 18327820 (Pubitemid 351628638)
3. CO da Fonseca JA Landeiro SS Clark T Quirico-Santos MG da Costa Carvalho CR Gattass 2006 Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol Surg Neurol 65 Suppl 1 S1:2 S1:8 (discussion S1:8-S1:9)
4. CO da Fonseca M Masini D Futuro R Caetano CR Gattass T Quirico-Santos 2006 Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review Surg Neurol 66 611 615 10.1016/j.surneu.2006.02.034 17145324 (Pubitemid 44827176)
5. CO da Fonseca R Linden D Futuro CR Gattass T Quirico-Santos 2008 Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol Arch Immunol Ther Exp (Warsz) 56 267 276 10.1007/s00005-008-0027-0
6. CO da Fonseca G Schwartsmann J Fischer J Nagel D Futuro T Quirico-Santos CR Gattass 2008 Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas Surg Neurol 70 259 266 10.1016/j.surneu.2007.07.040 18295834 (discussion 266-257)
7. CO da Fonseca JT Silva IR Lins M Simao A Arnobio D Futuro T Quirico-Santos 2009 Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol Invest New Drugs 13 557 564 10.1007/s10637-008-9215-3
8. M Diehn C Nardini DS Wang S McGovern M Jayaraman Y Liang K Aldape S Cha MD Kuo 2008 Identification of noninvasive imaging surrogates for brain tumor gene-expression modules Proc Natl Acad Sci USA 105 5213 5218 1:CAS:528:DC%2BD1cXksVGhtLg%3D 10.1073/pnas.0801279105 18362333 (Pubitemid 351738536)
9. D Figarella-Branger C Colin B Coulibaly B Quilichini A Maues De Paula C Fernandez C Bouvier 2008 Histological and molecular classification of gliomas Rev Neurol (Paris) 164 505 515 1:STN:280:DC%2BD1cvotl2gug%3D%3D
10. LA Gravendeel MC Kouwenhoven O Gevaert JJ de Rooi AP Stubbs JE Duijm A Daemen FE Bleeker LB Bralten NK Kloosterhof B De Moor PH Eilers PJ van der Spek JM Kros PA Sillevis Smitt MJ van den Bent PJ French 2009 Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology Cancer Res 69 9065 9072 1:CAS:528:DC%2BD1MXhsV2itLnO 10.1158/0008-5472.CAN-09- 2307 19920198
11. R Hashizume T Ozawa SM Gryaznov AW Bollen KR Lamborn WH Frey 2nd DF Deen 2008 New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163 Neuro Oncol 10 112 120 1:CAS:528: DC%2BD1cXls1Gjs7w%3D 10.1215/15228517-2007-052 18287341
12. AB Heimberger D Suki D Yang W Shi K Aldape 2005 The natural history of EGFR and EGFRvIII in glioblastoma patients J Transl Med 3 38 43 10.1186/1479-5876-3-38 16236164 (Pubitemid 41582047)
13. TC Johannessen R Bjerkvig BB Tysnes 2008 DNA repair and cancer stem-like cells-potential partners in glioma drug resistance? Cancer Treat Rev 34 558 567 1:CAS:528:DC%2BD1cXhtV2is7%2FF 10.1016/j.ctrv.2008.03.125 18501520
14. P Kleihues H Ohgaki 1999 Primary and secondary glioblastomas: from concept to clinical diagnosis Neuro Oncol 1 44 51 1:STN:280: DC%2BD3MrgtFCktg%3D%3D 11550301
15. F Lefranc V Facchini R Kiss 2007 Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas Oncologist 12 1395 1403 1:CAS:528:DC%2BD1cXhslSntLk%3D 10.1634/theoncologist.12- 12-1395 18165616
16. NG Rainov A Soling V Heidecke 2006 Novel therapies for malignant gliomas: a local affair? Neurosurg Focus 20 E9 16709040
17. Y Rong F Hu R Huang N Mackman JM Horowitz RL Jensen DL Durden EG Van Meir DJ Brat 2006 Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms Cancer Res 66 7067 7074 1:CAS:528: DC%2BD28XmvFGkt78%3D 10.1158/0008-5472.CAN-06-0346 16849552 (Pubitemid 44197683)
18. S Sathornsumetee JN Rich 2008 Designer therapies for glioblastoma multiforme Ann N Y Acad Sci 1142 108 132 1:CAS:528:DC%2BD1cXhsV2hsb7O 10.1196/annals.1444.009 18990124
19. S Scoccianti B Detti A Sardaro A Iannalfi I Meattini BG Leonulli S Borghesi F Martinelli L Bordi F Ammannati G Biti 2008 Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience Anticancer Drugs 19 613 620 1:CAS:528:DC%2BD1cXms1yru7g%3D 10.1097/CAD.0b013e3283005075 18525321
20. AM Stark A Nabavi HM Mehdorn U Blomer 2005 Glioblastoma multiforme-report of 267 cases treated at a single institution Surg Neurol 63 162 169 10.1016/j.surneu.2004.01.028 15680662 (Pubitemid 40174904)
21. J van Genugten P Leffers B Baumert H Tjon-a-Fat A Twijnstra 2010 Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice J Neurooncol 96 249 257 1:CAS:528:DC%2BC3cXptl2qtA%3D%3D 10.1007/s11060-009-9956-7 19582373